ContributorsPublishersAdvertisers

FDA Grants Priority Review to Olaparib for Adjuvant Treatment BRCA-mutated HER2- High-Risk eBC

targetedonc.com
 2021-11-30

Cover picture for the articleFindings from the phase 3 OlympiA led to the filing of a supplemental new drug application for olaparib as adjuvant treatment of BRCA-mutated HER2-negative high-risk early breast cancer. The FDA has accepted the supplemental new drug application (sNDA) for olaparib (Lynparza) and granted it priority review for the adjuvant...

www.targetedonc.com

Comments / 0

Comments / 0